BACKGROUND: Diagnosis of acute hepatitis E has been based in many clinics predominantly on detection of anti-HEV (hepatitis E virus) antibody. Now, new assays have been developed to detect other HEV markers. Our aim was to investigate the relationships among HEV diagnostic markers and liver function markers in acute hepatitis E. METHODS: Seventy serum samples were collected from non-A, non-B, non-C acute hepatitis patients and tested for HEV markers (HEV antigen and RNA and anti-HEV IgM) and markers of liver function [alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total iron binding capacity (TBA), gamma-glutamyl transferase (GGT), total bilirubin (TBIL), and direct bilirubin (DBIL)]. Partial open reading frame (ORF) 2 sequences from HEV RNA-positive samples were cloned and analyzed. RESULTS: The concordances between HEV antigen and HEV RNA and between HEV antigen and anti-HEV IgM were 77.1% and 72.9%, respectively, with significant correlations, while that between HEV RNA and anti-HEV IgM was 61.4% with no significant correlation. Eleven of 25 samples negative for anti-HEV IgM were positive for HEV antigen. The ALT, AST, ALP, TBA, GGT, TBIL, and DBIL levels did not differ significantly between the anti-HEV IgM-positive and -negative groups. However, the ALT, AST, ALP, TBA, and GGT levels were significantly higher in the HEV antigen-positive group than in the HEV antigennegative group. All of the HEV isolates cloned belonged to genotype 4. CONCLUSIONS: HEV antigen was highly correlated with HEV RNA and elevated ALT, AST, ALP, TBA, and GGT levels. Testing for HEV antigen in combination with anti-HEV IgM is useful for the diagnosis of HEV infection.
BACKGROUND: Diagnosis of acute hepatitis E has been based in many clinics predominantly on detection of anti-HEV (hepatitis E virus) antibody. Now, new assays have been developed to detect other HEV markers. Our aim was to investigate the relationships among HEV diagnostic markers and liver function markers in acute hepatitis E. METHODS: Seventy serum samples were collected from non-A, non-B, non-C acute hepatitispatients and tested for HEV markers (HEV antigen and RNA and anti-HEV IgM) and markers of liver function [alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total iron binding capacity (TBA), gamma-glutamyl transferase (GGT), total bilirubin (TBIL), and direct bilirubin (DBIL)]. Partial open reading frame (ORF) 2 sequences from HEV RNA-positive samples were cloned and analyzed. RESULTS: The concordances between HEV antigen and HEV RNA and between HEV antigen and anti-HEV IgM were 77.1% and 72.9%, respectively, with significant correlations, while that between HEV RNA and anti-HEV IgM was 61.4% with no significant correlation. Eleven of 25 samples negative for anti-HEV IgM were positive for HEV antigen. The ALT, AST, ALP, TBA, GGT, TBIL, and DBIL levels did not differ significantly between the anti-HEV IgM-positive and -negative groups. However, the ALT, AST, ALP, TBA, and GGT levels were significantly higher in the HEV antigen-positive group than in the HEV antigennegative group. All of the HEV isolates cloned belonged to genotype 4. CONCLUSIONS: HEV antigen was highly correlated with HEV RNA and elevated ALT, AST, ALP, TBA, and GGT levels. Testing for HEV antigen in combination with anti-HEV IgM is useful for the diagnosis of HEV infection.
Authors: O Velázquez; H C Stetler; C Avila; G Ornelas; C Alvarez; S C Hadler; D W Bradley; J Sepúlveda Journal: JAMA Date: 1990-06-27 Impact factor: 56.272
Authors: X J Meng; P G Halbur; M S Shapiro; S Govindarajan; J D Bruna; I K Mushahwar; R H Purcell; S U Emerson Journal: J Virol Date: 1998-12 Impact factor: 5.103
Authors: H van Cuyck-Gandre; J D Caudill; H Y Zhang; C F Longer; C Molinie; R Roue; R Deloince; P Coursaget; N N Mamouth; Y Buisson Journal: Am J Trop Med Hyg Date: 1996-02 Impact factor: 2.345
Authors: Andrew A Adjei; Yao Tettey; John T Aviyase; Clement Adu-Gyamfi; Julius A Mingle; Edmund T Nartey Journal: Virol J Date: 2010-11-22 Impact factor: 4.099
Authors: S Van Hees; S Bourgeois; H Van Vlierberghe; T Sersté; S Francque; P Michielsen; D Sprengers; H Reynaert; J Henrion; S Negrin Dastis; J Delwaide; L Lasser; J Decaestecker; H Orlent; F Janssens; G Robaeys; I Colle; P Stärkel; C Moreno; F Nevens; T Vanwolleghem Journal: Aliment Pharmacol Ther Date: 2018-03-02 Impact factor: 8.171